SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as community sentiment balances between bullish technical setups and cautious skepticism regarding its long-term utility. Traders are actively debating potential breakout levels while watching for broader market momentum to influence the coin's next move.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative momentum as investors rotate into Japanese blockchain projects and IoT-focused tokens. While community members are polarized between long-term accumulation and skepticism regarding project leadership and ecosystem expansion, active discussions remain centered on potential technical breakout patterns and broader data economy narratives.

Ascend is a prediction perpetuals platform that allows you to trade prediction markets with up to 100x leverage. Ascend is multi-chain, ZK-settled on Midnight, secured by Cardano. Ascend turns prediction markets into real-time, tradable markets. Instead of simply betting on outcomes and waiting for resolution, users can trade the probability of events (like BTC hitting $100K) using a perpetual-style engine, entering and exiting positions anytime. Trades are executed off-chain for speed and then batch-settled on Midnight using zero-knowledge (ZK) proofs, giving users a seamless experience with strong on-chain guarantees. This creates a more dynamic, liquid, and capital-efficient way to trade information and belief.

Project Ascend

Project Ascend is gaining significant traction as the community anticipates its upcoming mainnet launch and the integration of new features like liquid staking and a perpetual decentralized exchange. Investors are actively discussing the project's growth potential and ecosystem expansion while closely monitoring recent consolidation patterns.

ARK ETF Trust - ARK Space & Defense Innovation ETF

ARK Space Exploration & Innovation ETF

The ARK Space Exploration & Innovation ETF is garnering significant attention as investors speculate on its potential to capitalize on the growing space economy, particularly with ongoing excitement surrounding a possible SpaceX IPO. Community members are actively debating the fund's current holdings and comparing it to other space-focused investment vehicles while watching for future portfolio shifts.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is active and buzzing with speculative momentum as traders rotate between $MULN and associated tokens, fueled by community-led 'pump' narratives. Despite persistent warnings from some users about the project's controversial history, participants are rallying around high-risk, low-market-cap trading strategies in hopes of repeating past volatility.

Pump.fun

Pump.fun is generating significant community conversation as traders discuss its revenue-sharing model and ongoing ecosystem developments on Solana. While some community members remain focused on long-term accumulation and bullish sentiment, others are debating the sustainability of the platform amidst broader scrutiny of the meme coin sector.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is gaining significant community attention as investors highlight its deflationary burn mechanisms and expanding decentralized AI ecosystem, with many participants actively discussing potential price momentum fueled by privacy-focused AI narratives. The conversation is currently dominated by 'true long' bulls who view the token as a long-term play on artificial intelligence, frequently comparing its current market cap to other sector leaders while anticipating further ecosystem developments.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending as investors closely monitor a pivotal mid-2026 Phase 1 clinical readout for its lead asset, STRO-004, which is being positioned as a next-generation ADC to challenge established market competitors. The community is actively debating the company's long-term valuation, the strategic significance of its cell-free manufacturing platform, and the potential for a high-value M&A or partnership event following recent analyst coverage.

Brinker International, Inc. engages in owning, developing, and franchising Chili's Grill and Bar and Maggiano's Little Italy restaurant brands. It operates through the Chili's and Maggiano's segments. The Chili's segment includes the results of company-owned Chili's restaurants in the U.S. and Canada as well as the results from its domestic and international franchise business. The Maggiano's segment refers to the results of company owned Maggiano's restaurants. The company was founded by Larry Lavine on March 13, 1975 and is headquartered in Dallas, TX.

Brinker International, Inc.

Brinker International, Inc. (EAT) has emerged as a standout performer in the restaurant sector, with investors pointing to robust same-store sales growth, traffic gains at Chili's, and successful menu innovation as key drivers behind the stock's recent momentum. The community is actively discussing the company's operational execution and its ability to maintain value-oriented appeal, though some participants remain cautious, debating the sustainability of current valuation levels and potential macro headwinds.

OpenAI pioneers large-language models like GPT and DALL·E, enabling advanced AI applications. Their research emphasizes both cutting-edge capability and responsible deployment strategies.

OpenAI PreStocks

Community sentiment remains polarized over OpenAI, with intense debate centering on its high-valuation secondary market activity, aggressive capital expenditure, and potential spin-off plans for its robotics and hardware divisions. While some investors view these developments as catalysts for broader tech growth, others are increasingly vocal about the risks of AI overinvestment and the long-term sustainability of the current AI funding model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATRA Crosses Above Average Analyst Target

In recent trading, shares of Atara Biotherapeutics Inc (Symbol: ATRA) have crossed above the average analyst 12-month target price of $9.33, changing hands for $9.93/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade...

<ul class="summary-bullets"><li>Atara is jointly developing the drug with Pierre Fabre Pharmaceuticals.</li><li>The FDA stated that a single-arm study using a historical control group could support a future marketing application.</li><li>FDA had rejected an initial application submitted by Atara in January 2026, raising concerns about the trial design and analysis.</li></ul>Shares of Atara Biotherapeutics (ATRA) surged more than 43% in morning trade on Thursday, recording their biggest single-day gains in more than two years, after the biotech firm announced a promising update from the U.S. Food and Drug Administration (FDA) tied to its experimental blood cancer therapy.<a href="https://stocktwits.com/symbol/ATRA">ATRA shares</a> also breached the 100-day moving average (100-DMA) for the first time in nearly four months.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AATRA"><img src="https://news.stocktwits-cdn.com/ATRA_jpg_7fc3a2b23b.webp" alt="ATRA.jpg"></a>Source: TradingView<h2 class="st-heading-2">FDA Talks Signal Resubmission Hopes For ATRA’s Immunotherapy</h2>Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application (BLA) for Tabelecleucel. The drug is used for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).The update followed a recent Type A meeting between the FDA, Atara, and its partner, Pierre Fabre Pharmaceuticals, after the agency issued a Complete Response Letter (CRL) earlier this year, stating that it could not approve the application in its current form.However, the FDA has now stated that a single-arm study using a historical control group could support a future marketing application. Pierre Fabre plans to include updated results from its Phase 3 study, including additional patient data and longer follow-up, as part of the resubmission package.Atara and Pierre Fabre are jointly developing the drug.<h2 class="st-heading-2">Why Did FDA Reject ATRA’s Initial Application?</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/atra-rises-on-pushing-for-meeting-with-fda-on-rare-disease-drug-rejection/cZdeli8RIP1">previously</a> declined to approve Tabelecleucel, stating the company’s study did not provide enough evidence for accelerated approval and raised concerns about the trial design and analysis.Pierre Fabre responded to the agency, providing additional explanations and arguing that the study was properly controlled and suitable to support the application. The company also submitted updated long-term efficacy data, along with supportive development and European post-marketing data, for a potential resubmission.<h2 class="st-heading-2">Retail Skeptical About ATRA’s Rally</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.However, one user stated the news did not justify the rally.<stembedurl>https://stocktwits.com/robanbieber/message/652581236</stembedurl>Another user called ATRA’s chart setup “neutral” and saw support between $6.50 and $7.<stembedurl>https://stocktwits.com/independentresearch1/message/652578353</stembedurl>ATRA shares have been under heavy selling pressure this year, slumping nearly 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-bulls-shrug-off-earnings-loss-retail-traders-eye-a-crucial-fda-deadline/cZXbg96ReQT">IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

 Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Equity

Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to...

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA The Gross Law Firm Reminds Atara...

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire...

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP...

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA Pomerantz Law Firm Announces the Filing of a Class Action Against Atara...

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky PR Newswire NEW YORK, April 29, 2026 NEW YORK, April 29, 2026...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$8.34
Prev Close	$9.93
Open	$9.65
Dividend Yield	0.00%
50-Day Moving Average	$5.31
Beta	2.22
Avg. Volume	64,042.83
PE Ratio	2.86

52-Week High	$19.15
52-Week Low	$3.92
Market Capitalization	$70.99M
EPS (Annual)	$2.57
Price to Book	-1.59
Revenue Per Employee	$8.63M

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRA News

ATRAAtara Biotherapeutics Inc